Curia Plans Expansion to Global Network of Sterile Fill-Finish Sites
Curia’s sterile fill-finish facility in Glasgow will add an integrated, isolator-based vial filling line and lyophilizer suitable for a broad range of drug product including highly potent capabilities, more than doubling current GMP batch size.
Antibody Drug Conjugates | 18/03/2025 | By Aishwarya
Novo Holdings Invests in Series A Launch Financing for Callio Therapeutics
The oversubscribed Series A financing was led by Frazier Life Sciences, with significant participation from Novo Holdings and other life sciences investors including Jeito Capital, Omega Funds, Norwest, ClavystBio, EDBI, Platanus, Pureos Bioventures and SEEDS Capital.
Antibody-drug Conjugates | 04/03/2025 | By Aishwarya | 104
Lantern Pharma Launches Innovative AI-Powered Module to Advance ADC Development for Cancer
The global ADC market is projected to reach USD 30.4 billion by 2028, growing at a CAGR of 41.7 percent, with several recently approved ADCs achieving blockbuster status with annual sales exceeding USD 1 billion.
Antibody-drug Conjugates | 28/01/2025 | By Aishwarya
NJ Bio Partners with Charles River to Accelerate ADC Development
The biggest benefit of the Charles River and NJ Bio alliance is that clients can receive seamless complementary services to enhance outcomes and accelerate time-to-market for their ADCs.
Antibody Drug Conjugates | 08/11/2024 | By Aishwarya
AstraZeneca to Establish USD 1.5 Billion Manufacturing Facility for ADCs in Singapore
AstraZeneca has decided to build a USD 1.5 billion manufacturing facility in Singapore for antibody-drug conjugates (ADCs), enhancing the global supply of its ADC portfolio.
Antibody-drug Conjugates | 20/05/2024 | By Aishwarya | 169
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy